Previous 10 | Next 10 |
2024-04-02 11:58:20 ET Summary EXAS has a unique regulatory advantage as the FDA and Congress work on extending the regulatory arm over the gene diagnostics sector. Cologuard remains EXAS's growth engine going into 2024. Revaluation in the gene diagnostics sector means that EX...
2024-04-02 10:00:25 ET More on Health Care Select Sector SPDR XLV: Fundamentals Don't Support Overweighting Health Care XLV: Low-Cost Exposure To A Defensive Sector, While Achieving Strong Performance Healthcare In 2024: Navigating The Biopharma Bull Run Eli ...
2024-04-01 11:30:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-03-29 10:45:03 ET Bristol-Myers Squibb Co. (BMY) BMY is trading UP for the last 5 days, and it at trading at $54.28 with volume of 9,234,665 and a one day change of $1.02 (1.92%). Bristol-Myers Squibb Co. has a 52-week low of 47.58 and a 52-week high of $71.07. The business's 5...
2024-03-28 15:13:00 ET More on Exact Sciences Exact Sciences Corporation (EXAS) Q4 2023 Earnings Call Transcript Exact Sciences Corporation 2023 Q4 - Results - Earnings Call Presentation Exact Sciences: Growing Revenue With An Innovative Approach To Oncology ...
Results indicate potential of a minimally invasive screening tool to detect most common form of Esophageal Cancer, a highly treatable cancer if caught early Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, in collaboration with Mayo Clinic ...
Company also receives national and regional Top Workplace honors from USA Today and Wisconsin State Journal Exact Sciences Corp. (NASDAQ: EXAS), a leading provider of cancer screening and diagnostic tests, today announced it has received the 2024 Gallup Exceptional Workplace...
2024-03-22 09:58:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
Cologuard Plus is only noninvasive test to be evaluated head-to-head against an independent fecal immunochemical test, which it significantly outperformed 20,000-participant BLUE-C study included 98 colorectal cancers and reflects racial and ethnic diversity of U.S. Company will host conf...
2024-03-13 14:01:40 ET More on Qiagen, Bio-Techne, etc. Qiagen N.V. 2023 Q4 - Results - Earnings Call Presentation Qiagen N.V. (QGEN) Q4 2023 Earnings Call Transcript Bio-Techne Corporation (TECH) Q2 2024 Earnings Call Transcript Qiagen upgraded at Morgan Sta...
News, Short Squeeze, Breakout and More Instantly...
Exact Sciences Corporation Company Name:
EXAS Stock Symbol:
NASDAQ Market:
Exact Sciences Corporation Website:
2024-07-11 08:28:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-07-08 08:30:00 ET To say that Exact Sciences (NASDAQ: EXAS) hasn't performed well on the stock market this year would be an understatement. Shares of the cancer-focused biotech are down by 41%. However, the healthcare company still has some fans on Wall Street. Cathie Wood ...
Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that the company plans to release its second quarter 2024 financial results after the close of the U.S. financial markets on July 31, 2024. Following the release, company management w...